TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16533939
Drug: Rosuvastatin 40
Normalized name: rosuvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 40 mg/d
Study: 11495620
Drug: Antibiotic administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotic administration via the catheter
Study: 9512207
Drug: Doxapram (3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxapram (3.5 mg kg(‐1) bolus followed by 1 mg kg(‐1) h(‐1) infusion)
Study: 8893893
Drug: First-line paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: First-line paclitaxel (200 mg/m2 as a 3-hour infusion) followed by second-line doxorubicin (75 mg/m2 as a bolus injection)
Study: 8893893
Drug: Second-line doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-line doxorubicin (75 mg/m2 as a bolus injection) followed by first-line paclitaxel (200 mg/m2 as a 3-hour infusion)
Study: 7000105
Drug: Probenecid 0.5
Normalized name: colchicine-probenecid 0.5 mg-500 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probenecid 0.5 g
Study: 7000105
Drug: Probenecid 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probenecid 1.0 g
Study: 7000105
Drug: Probenecid 0.5
Normalized name: colchicine-probenecid 0.5 mg-500 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probenecid 0.5 g (without pethidine premedication)
Study: 7000105
Drug: Probenecid (without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probenecid (without pethidine premedication, thiopentone 4 mg kg‐1)
Study: 28392509
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (25-mg agomelatine)
Study: 25575258
Drug: Gastrografin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastrografin (100 mL administered enterally)
Study: 25889222
Drug: COBRA Slim
Normalized name: benzalkonium chloride Topical Foam [DigiClean Slim-Line]
Approvals — FDA: no, EMA: no, PMDA: no
Description: COBRA Slim (MTX with prednisone bridging, starting at 30 mg and tapered to 5 mg daily from week 6)
Study: 25889222
Drug: MTX-TSU (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX-TSU (15 mg of MTX weekly)
Study: 18451718
Drug: NSAIDs (effervescent
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAIDs (effervescent aspirin)
Study: 10851109
Drug: Nimesulide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimesulide (100 mg twice daily for 10 days)
Study: 2015162
Drug: Ibuprofen (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (600 mg three times daily for 10 days)
Study: 9507415
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (idiopathic cases)
Study: 7810816
Drug: Praziquantel 40
Normalized name: PRAZIQUANTEL 40 mg in 1 mL ORAL SOLUTION [A Vial]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel 40 mg/kg as a single oral dose
Study: 2467132
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg single oral dose
Study: 29198820
Drug: Oral amoxicillin
Normalized name: amoxicillin Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amoxicillin plus resveratrol (AX + RV)
Study: 29198820
Drug: Oral amoxicillin
Normalized name: amoxicillin Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amoxicillin plus placebo (AX + placebo)
Study: 28743659
Drug: Reflexology intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reflexology intervention (four weekly sessions, caregiver-delivered, 30-minute protocol)
Study: 26367865
Drug: Ibudilast 40
Normalized name: ibudilast
DrugBank: Ibudilast (DB05266)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Ibudilast 40 mg twice daily for 8 weeks
Study: 12699517
Drug: Rocuronium 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.6 mg kg(‐1) and lidocaine 1.5 mg kg(‐1)
Study: 11271285
Drug: Histidine‐Tryptophane‐Ketoglutarate (HTK)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histidine‐Tryptophane‐Ketoglutarate (HTK) solution
Study: 11271285
Drug: Euro‐Collins (EC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euro‐Collins (EC) solution
Study: 2853765
Drug: Lisinopril (20‐80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (20‐80 mg/day)
Study: 2853765
Drug: Atenolol (50‐200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (50‐200 mg/day)
Study: 23747044
Drug: Clopidogrel treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel treatment with high residual platelet reactivity (RPR) diagnosed on P2Y₁₂ reaction units >230
Study: 23747044
Drug: Good responders
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Good responders to clopidogrel treatment
Study: 30633139
Drug: Riboflavin 400
Normalized name: riboflavin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riboflavin 400 mg
Study: 24905030
Drug: 0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg robatumumab followed by 10 mg/kg biweekly in P2
Study: 24905030
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg robatumumab in P2
Study: 24905030
Drug: 0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg robatumumab
Study: 12396296
Drug: Liquid Gaviscon
Normalized name: Gaviscon Oral Liquid Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid Gaviscon (20 mL)
Study: 12396296
Drug: Gaviscon Advance
Normalized name: Gaviscon
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gaviscon Advance (10 mL)
Study: 8990771
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIG) 500 mg/kg
Study: 7284972
Drug: Weekly oral
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly oral 5-fluorouracil (5-FU)
Study: 7284972
Drug: Weekly intravenous
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly intravenous 5-fluorouracil (5-FU)
Study: 23974035
Drug: Weight loss
Normalized name: HERBAL WEIGHT LOSS AID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight loss only treatment (WL)
Study: 21329622
Drug: Hyoscine butylbromide
Normalized name: Hyoscine butylbromide
DrugBank: Butylscopolamine (DB09300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyoscine butylbromide tablets
Study: 21329622
Drug: Hyoscine butylbromide
Normalized name: Hyoscine butylbromide
DrugBank: Butylscopolamine (DB09300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyoscine butylbromide capsules
Study: 19433701
Drug: Exposure to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure to small branded promotional items for Lipitor (atorvastatin)
Study: 16724678
Drug: Eicosapentaenoic acid
Normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eicosapentaenoic acid (EPA) at a dose of 2400 mg/day for 12 weeks
Study: 30412630
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (enoxaparin)
Study: 9143868
Drug: Controlled diffusion
Normalized name: LUNG DIFFUSION GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled diffusion diltiazem (180 mg taken in the morning)
Study: 9143868
Drug: Conventional release
Normalized name: Product manufactured as conventional release gas for inhalation (product)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional release diltiazem (90 mg taken twice daily)
Study: 7956413
Drug: Metaproterenol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metaproterenol (1 mL 0.5% in 3 mL saline solution)
Study: 7956413
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (4 mL)
Study: 3238472
Drug: Full-dose HB
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose HB vaccine (Group A, 69 infants)
Study: 3238472
Drug: Half-dose HB
Normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Half-dose HB vaccine (Group B, 70 infants)
Study: 23758673
Drug: Kivia powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kivia powder (5.5 g daily for four weeks)
Study: 12939876
Drug: Fenazid (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenazid (0.5 g daily for 2 months)
Study: 12939876
Drug: Routine antituberculous
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine antituberculous chemotherapy regimen including isoniazid
Study: 10617523
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of problem solving treatment and antidepressant medication
Study: 10617523
Drug: Problem solving
Normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem solving treatment delivered by practice nurses
Study: 10617523
Drug: Problem solving
Normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem solving treatment delivered by general practitioners
Study: 9169747
Drug: Whole-cell pertussis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-cell pertussis vaccine (wP)
Study: 9169747
Drug: Acellular pertussis
Normalized name: Acellular pertussis vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acellular pertussis vaccine (aP-SB)
Study: 9169747
Drug: Acellular pertussis
Normalized name: Acellular pertussis vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acellular pertussis vaccine (aP-CB)
Study: 9169747
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (DT or unresponsive pertussis vaccine recipients)
Study: 8466237
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg nebulised budesonide
Study: 3512507
Drug: Antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylaxis (methicillin 2 g and netilmicin 200 mg, three doses)
Study: 27681077
Drug: Synbiotic supplementation
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synbiotic supplementation (daily capsule containing Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium bifidum at 2×10^9 CFU/g each plus 800 mg inulin) for 6 weeks
Study: 24947504
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of chlorogenic acids (412 μmol)
Study: 24947504
Drug: Medium dose
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium dose of chlorogenic acids (635 μmol)
Study: 24947504
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of chlorogenic acids (795 μmol)
Study: 22544046
Drug: Cyproheptadine 4
Normalized name: cyproheptadine 4 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproheptadine 4 mg three times per day for 12 weeks
Study: 15855489
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg infusion of isoniazid
Study: 15855489
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg oral single dose of isoniazid
Study: 15855489
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg oral single dose of isoniazid
Study: 8524425
Drug: Sucralfate suspension
Normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucralfate suspension 2 g daily (twice daily for 6 months)
Study: 18556965
Drug: Placebo (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (twice daily for 6 months)
Study: 7048519
Drug: Cephalosporin (oral)
Normalized name: Cephalosporium roseum
DrugBank: Cephalosporium roseum (DB10932)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalosporin (oral)
Study: 27206939
Drug: Evacetrapib 500
Normalized name: Evacetrapib
DrugBank: Evacetrapib (DB11655)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evacetrapib 500 mg/d
Study: 27206939
Drug: Evacetrapib plus
Normalized name: Evacetrapib
DrugBank: Evacetrapib (DB11655)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evacetrapib plus statins (100 mg evacetrapib + simvastatin 40 mg/d, atorvastatin 20 mg/d, or rosuvastatin 10 mg/d)
Study: 17553812
Drug: Piperacillin-tazobactam/amoxicillin-clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin-tazobactam/amoxicillin-clavulanate
Study: 9715790
Drug: Intranasal ANG
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal ANG II (400 microg)
Study: 9715790
Drug: Intravenous ANG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ANG II (2.5 microg)
Study: 2555803
Drug: Oxycodone (0.13
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone (0.13 mg/kg)
Study: 100808
Drug: Diphenhydramine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenhydramine (100 mg)
Study: 31446629
Drug: Sugar consumption
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar consumption restricted to less than 3% of total daily calories for 8 weeks
Study: 30925951
Drug: Laparoscopic surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic surgery combined with GnRH agonist (GnRH‐a)
Study: 23688546
Drug: Low-dose adjuvanted
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose adjuvanted quadrivalent influenza vaccine (LD QIV-AS)
Study: 23688546
Drug: Low-dose adjuvanted
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose adjuvanted trivalent influenza vaccine (LD TIV-AS)
Study: 12234948
Drug: Intra-arterial vitamin
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial vitamin C (24 mg/min)
Study: 8088389
Drug: General anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anaesthesia (GA; n = 9) followed by intramuscular analgesics
Study: 31440823
Drug: Aprepitant plus
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprepitant plus ondansetron (Arm-A: ondansetron 8 mg days 1-5 with aprepitant day 1: 125 mg, days 2-5: 80 mg)
Study: 21417952
Drug: Dalteparin (5000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin (5000 IU once daily)
Study: 15446778
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (5000 IU twice daily)
Study: 19877975
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of MPH and CLON
Study: 9989682
Drug: Tocotrienol group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocotrienol group (4 capsules daily, each containing 35 mg tocotrienols and 20 mg alpha-tocopherol)
Study: 9989682
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (4 capsules daily, each providing 20 mg alpha-tocopherol)
Study: 6965333
Drug: Patients who
Normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who underwent surgery after medical therapy failed
Study: 31468659
Drug: Aleglitazar 150
Normalized name: Aleglitazar
DrugBank: Aleglitazar (DB08915)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aleglitazar 150 μg
Study: 28726232
Drug: Topiramate 50
Normalized name: topiramate 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate 50 mg/day for three months
Study: 26484767
Drug: Topical Bimatoprost
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Bimatoprost 0.01%
Study: 23175769
Drug: Revaccination with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Revaccination with standard HBV vaccine series in HIV-1-infected initial nonresponders
Study: 21293987
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy until cessation of breastfeeding
Study: 21293987
Drug: Short course
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short course zidovudine monotherapy
Study: 17943989
Drug: Pegylated interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegylated interferon (PEG‐IFN) alpha‐2b (1.5 mug/kg/week) plus oral ribavirin (10.6 mg/kg/day) for 24 weeks (Group A)
Study: 17943989
Drug: Pegylated interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegylated interferon (PEG‐IFN) alpha‐2b (1.5 mug/kg/week) plus oral ribavirin (10.6 mg/kg/day) for 36 weeks (Group B)
Study: 17943989
Drug: Pegylated interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegylated interferon (PEG‐IFN) alpha‐2b (1.5 mug/kg/week) plus oral ribavirin (10.6 mg/kg/day) for 48 weeks (Group C)
Study: 17943989
Drug: Control group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group: Pegylated interferon (PEG‐IFN) alpha‐2b (1.5 mug/kg/week) plus oral ribavirin (10.6 mg/kg/day) for a fixed duration of 48 weeks
Study: 14764787
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate (TE) 25 mg/wk
Study: 14764787
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate (TE) 50 mg/wk
Study: 14764787
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate (TE) 125 mg/wk
Study: 14764787
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate (TE) 600 mg/wk
Study: 25015176
Drug: UMEC/VI 125/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: UMEC/VI 125/25 mcg
Study: 25015176
Drug: UMEC 125
Normalized name: Umecta
Approvals — FDA: no, EMA: no, PMDA: no
Description: UMEC 125 mcg
Study: 31747236
Drug: VI 25
Normalized name: VITRAKVI 25mg Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: VI 25 mcg
Study: 23089217
Drug: Organopathic medicines
Normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Organopathic medicines (OM)
Study: 23089217
Drug: Constitutional medicines
Normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Constitutional medicines (CM)
Study: 23089217
Drug: Combined homeopathic
Normalized name: Urtica urens homeopathic preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined homeopathic treatment (BCOM)
Study: 19047814
Drug: Nasal saline
Normalized name: Nasal Saline
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nasal saline irrigation and tapered topical steroid
Study: 27859588
Drug: Client-centered therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Client-centered therapy
Study: 9403918
Drug: Client-centered therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Client-centered therapy with additional behavioral exposure treatment
Study: 9403918
Drug: Client-centered therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Client-centered therapy and behavioral exposure treatment
Study: 8478043
Drug: Low-dose chlorthalidone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose chlorthalidone
Study: 23099060
Drug: L-carnosine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnosine (2 g/day)
Study: 20070756
Drug: Osstem SSII
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osstem SSII Implant system
Study: 20070756
Drug: Standard Straumann
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Straumann Dental Implant System
Study: 9084336
Drug: Chlorhexidine administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine administration method 1
Study: 9084336
Drug: Chlorhexidine administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine administration method 2
Study: 1831083
Drug: SCH 34826
Normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCH 34826 400 mg
Study: 1831083
Drug: SCH 34826
Normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCH 34826 800 mg
Study: 1831083
Drug: SCH 34826
Normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCH 34826 1600 mg
Study: 26272719
Drug: 3 mL
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mL of 2% prilocaine (60 mg)
Study: 26272719
Drug: 3 mL
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mL of 0.4% plain ropivacaine (12 mg)
Study: 19205780
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g of beta-glucan
Study: 19205780
Drug: Beta-glucan content
Normalized name: Beta glucan
DrugBank: Yeast beta-D-glucan (DB19271)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-glucan content (0, 2.5, 5, 7.5, and 10 g)
Study: 15590253
Drug: Oral fiberoptic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fiberoptic intubation
Study: 11755552
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg of conjugated estrogens plus 2.5 mg of medroxyprogesterone acetate
Study: 11755552
Drug: Diabetes on
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diabetes on treatment (insulin)
Study: 11755552
Drug: Diabetes on
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diabetes on treatment (oral medications)
Study: 9203680
Drug: Antiparasitic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiparasitic therapy
Study: 7963049
Drug: Structured medication
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured medication education